Innovating Works

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO

Activa
Mostrando 1 al 20 de 22 resultados
PIA: Photocatalytic Industrial Applications UNIVERSIDAD AUTÓNOMA DE MADRID tramitó un HORIZON EUROPE: The European Union has been challenged to contribute to the global aim of providing sustainable solutions to the current and future needs on...
2024-05-30 - 2028-12-31 | Financiado
NAVIPP: New AntiVirals for Infections with Pandemic Potential EUROPEAN RESEARCH INFRASTRUCTURE ON HIGHLY PATHOGENIC AGENTS tramitó un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-03 For infectious disease management and control, vaccines are considered golden countermeasures. but are not the most adequate tool for mitiga...
2023-11-22 - 2028-12-31 | Financiado
UNITE4TB: ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM tramitó un H2020: H2020-JTI-IMI2-2020-20-two-stage Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for...
2021-06-29 - 2028-05-31 | Financiado
ERA4TB: EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS UNIVERSIDAD CARLOS III DE MADRID tramitó un H2020: H2020-JTI-IMI2-2018-15-two-stage The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms...
2019-12-12 - 2025-12-31 | Financiado
GNA NOW: NOVEL GRAM NEGATIVE ANTIBIOTIC NOW STICHTING LYGATURE tramitó un H2020: H2020-JTI-IMI2-2018-16-single-stage AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit rep...
2019-06-17 - 2025-12-31 | Financiado
TRIC-TB: Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators... BIOVERSYS AG tramitó un H2020: H2020-JTI-IMI2-2018-16-single-stage Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active T...
2019-05-28 - 2024-02-29 | Financiado
LYMPHVECs: Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to... GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un H2020: H2020-MSCA-IF-2017 According to the WHO there are 8 million persons chronically infected by Chagas disease (CD) resulting in 12.000 reported deaths annually. C...
2018-04-12 - 2021-03-31 | Financiado
I-CONSENT: Improving the guidelines for Informed Consent including vulnerable populations under a gender pers... Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana tramitó un H2020: H2020-SwafS-2016-17 The informed consent (IC) process allows the subject to voluntarily decide whether or not his/her participation in research. Generally, ICs...
2017-04-21 - 2021-03-31 | Financiado
anTBiotic: AnTBiotic progressing TB drug candidates to clinical proof of concept GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un H2020: H2020-SC1-2016-2017 Tuberculosis (TB) today rivals HIV/AIDS as the leading cause of death from infectious diseases. The number of TB patients has never been hig...
2016-12-02 - 2022-06-30 | Financiado
PREDICT-TB: Model-based preclinical development of anti-tuberculosis drug combinations GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un FP6: Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and...
2012-05-01 - 2017-10-31 | Financiado
ORCHID: Open Collaborative Model for Tuberculosis Lead Optimisation GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un FP7: "Early stage Drug Discovery efforts over the last 5 years have resulted in the identification of a number of promising lead compounds in the...
Financiado
PREDICT-TB: Model based preclinical development of anti tuberculosis drug combinations GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO tramitó un FP7: Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and...
Financiado
UPSTREAM: European Research Training in the Ubiquitin Proteasome System ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE tramitó un FP7: The main objective of the international training network UPStream is the training of a novel generation of European scientist in a critical...
Financiado
PARAMET: A systematic analysis of parasite metabolism from metabolism to intervention UNIVERSITY OF GLASGOW tramitó un FP7: Parasites exact a devastating toll on health and economic productivity, infecting man and also domestic livestock. Drugs used to combat par...
Financiado
FISHFORPHARMA: Training Network on Zebrafish Infection Models for Pharmaceutical Screens UNIVERSITEIT LEIDEN tramitó un FP7: Infectious diseases caused by pathogenic micro-organisms are major causes of death, disability, and social and economic disruption for milli...
Financiado
OPENMEDCHEM: Medicinal Chemistry Open Innovation Doctorates UNIVERSITEIT ANTWERPEN tramitó un FP7: The establishment of influential public and private public partnerships fostering true collaboration between big Pharma and universities for...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.